Log in

NASDAQ:RIGLRigel Pharmaceuticals Stock Price, Forecast & News

$1.78
-0.04 (-2.20 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.77
Now: $1.78
$1.85
50-Day Range
$1.78
MA: $1.89
$2.05
52-Week Range
$1.23
Now: $1.78
$3.10
Volume1.57 million shs
Average Volume2.14 million shs
Market Capitalization$300.05 million
P/E RatioN/A
Dividend YieldN/A
Beta1.26
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The company's clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases. The company has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to pursue research related to MDM2 inhibitors, a novel class of drug targets called ligases, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Tavalisse. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is based in South San Francisco, California.
Read More
Rigel Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.46 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.29 million
Book Value$0.32 per share

Profitability

Net Income$-66,890,000.00

Miscellaneous

Employees158
Market Cap$300.05 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

How has Rigel Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RIGL stock has decreased by 1.7% and is now trading at $1.78. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Rigel Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Rigel Pharmaceuticals.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Rigel Pharmaceuticals.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) released its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported $0.13 EPS for the quarter, hitting the consensus estimate of $0.13. The biotechnology company earned $55.76 million during the quarter, compared to analysts' expectations of $56.94 million. Rigel Pharmaceuticals had a negative return on equity of 40.15% and a negative net margin of 27.39%. View Rigel Pharmaceuticals' earnings history.

What price target have analysts set for RIGL?

4 Wall Street analysts have issued twelve-month price objectives for Rigel Pharmaceuticals' shares. Their forecasts range from $6.00 to $8.00. On average, they anticipate Rigel Pharmaceuticals' stock price to reach $7.33 in the next year. This suggests a possible upside of 312.0% from the stock's current price. View analysts' price targets for Rigel Pharmaceuticals.

Has Rigel Pharmaceuticals been receiving favorable news coverage?

Media coverage about RIGL stock has been trending neutral on Saturday, according to InfoTrie Sentiment. The research group ranks the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Rigel Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Rigel Pharmaceuticals.

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include Rite Aid (RAD), Geron (GERN), Terra Tech (TRTC), TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Catalyst Pharmaceuticals (CPRX), Novavax (NVAX), Verastem (VSTM) and Aurora Cannabis (ACB).

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the following people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 58)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 54)
  • Dr. Anne-Marie S. Duliege, Exec. VP & Chief Medical Officer (Age 60)
  • Mr. Eldon C. Mayer III, M.B.A., Exec. VP & Chief Commercial Officer (Age 58)
  • Dr. Thomas A. Raffin, Co-Founder (Age 72)

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

Who are Rigel Pharmaceuticals' major shareholders?

Rigel Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Diversified Trust Co (0.03%). Company insiders that own Rigel Pharmaceuticals stock include Anne-Marie Duliege, Dean L Schorno, Eldon C Mayer III, Nelson Cabatuan and Raul R Rodriguez. View institutional ownership trends for Rigel Pharmaceuticals.

Which major investors are buying Rigel Pharmaceuticals stock?

RIGL stock was purchased by a variety of institutional investors in the last quarter, including Diversified Trust Co. Company insiders that have bought Rigel Pharmaceuticals stock in the last two years include Dean L Schorno, Eldon C Mayer III, and Raul R Rodriguez. View insider buying and selling activity for Rigel Pharmaceuticals.

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $1.78.

How big of a company is Rigel Pharmaceuticals?

Rigel Pharmaceuticals has a market capitalization of $300.05 million and generates $59.29 million in revenue each year. The biotechnology company earns $-66,890,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. Rigel Pharmaceuticals employs 158 workers across the globe.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is www.rigel.com.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.